1 Subjects: “...Biological Products / therapeutic use...”

2 Subjects: “...Biological Products / therapeutic use...”

3 “.... The production of methamphetamine is dangerous and produces large volumes of toxic chemical waste. In 2006...”

4 “... associated side effects including drowsiness, dizziness and dry mouth; according to the product monograph...”

5 “.... The production of methamphetamine is dangerous and produces large volumes of toxic chemical waste. In 2006...”

6 “... associated side effects including drowsiness, dizziness and dry mouth; according to the product monograph...”

7 “..., administration of blood product) in pre-hospital settings, and to examine clinical guidelines regarding the use...”

8 “..., administration of blood product) in pre-hospital settings, and to examine clinical guidelines regarding the use...”

9 “... or combination product of buprenorphine with naloxone (BUP-NAL) formulations for the treatment of OUD....”

10

11 “... or combination product of buprenorphine with naloxone (BUP-NAL) formulations for the treatment of OUD....”

12

13

14

15 “.... For instance, the combination product piperacillin-tazobactam is often referred to as monotherapy unless...”

16 “.... For instance, the combination product piperacillin-tazobactam is often referred to as monotherapy unless...”

17 “...In 2017, CADTH produced a Rapid Response report summarizing evidence on the clinical effectiveness...”

18 “...In 2017, CADTH produced a Rapid Response report summarizing evidence on the clinical effectiveness...”

19 “...), and received a recommendation of "do not list". CADTH has previously produced a Rapid Response Summary...”

20 “...), and received a recommendation of "do not list". CADTH has previously produced a Rapid Response Summary...”